Archive for the ‘Gene Therapy Research’ Category

March 4, 2013

redOrbit Staff & Wire Reports Your Universe Online

A coalition of 18 different research organizations has identified seven new genetic regions associated with an eye disorder that is a common cause of blindness in older individuals, according to a study published online Sunday in the journal Nature Genetics.

The AMD Gene Consortium study also confirmed that 12 regions of the human genome (also known as loci) previously identified by scientists were also associated with age-related macular degeneration (AMD).

According to the National Eye Institute (NEI), the research which was led by experts from the University of Michigan, Boston University, Vanderbilt University, and the University of Regensburg in Germany represents the most comprehensive genome-wide analysis of genetic variations associated with AMD.

Officials with Vanderbilt University Medical Center said that the research could point to new biological pathways and therapeutic targets for AMD. In addition, Jonathan Haines, Ph.D., director of the Nashville, Tennessee-based universitys Center for Human Genetics Research, said that their efforts have made it possible to explain nearly two-thirds of the genetics associated with the development of this degenerative eye condition.

The NEI, which is a part of the US National Institutes of Health and supported the AMD Gene Consortiums efforts, explained that the condition targets a persons macula, or the part of the retina responsible for central vision. The macula typically helps people in tasks that require sharp vision, including reading and driving. However, AMD makes those tasks more difficult and eventually impossible as it progresses, and there is no known cure.

In their research, the consortium looked at data for more than 17,000 of the estimated two million Americans currently suffering from AMD. The test subjects each had more advanced, severe forms of the condition, and their genetic information was compared to that of over 60,000 people not suffering from the condition.

The 19 loci that were found to be associated with AMD implicate a variety of biological functions, including regulation of the immune system, maintenance of cellular structure, growth and permeability of blood vessels, lipid metabolism and atherosclerosis, researchers from Boston University Medical Center explained in a statement.

Further comprehensive DNA analysis of the areas around the 19 loci identified by the AMD Gene Consortium could turn up undiscovered rare genetic variants with a disproportionately large effect on AMD risk, they added. Discovery of such genes could greatly advance scientists understanding of AMD pathogenesis and their quest for more effective treatments.

More:
The Genetics Behind Age-related Macular Degeneration Detailed In New Study

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGI), a leader in oncology-focused personalized medicine, today announced it has received CLIA and New York State approvals for clinical use of its proprietary mature B-cell neoplasm array or MatBA (patent 13/475,034) for diffuse large B-cell lymphoma. MatBA-DLBCL will assist clinicians in the diagnosis and prognosis of DLBCL.

DLBCL is the most common form of non-Hodgkin lymphoma (NHL), a diverse group of hematological malignancies. An estimated 190,000 people in the United State suffer from DLBCL, and up to 24,500 new U.S. cases diagnosed each year, which accounts for up to 40% of all NHL cases. Newly-diagnosed patients have a median age of 64 years, and disease progression and outcomes vary widely, due in part to the genomic characteristics of each individual patients cancer. This creates a strong clinical need for accurate and molecularly-informed prognostic testing both at the time of initial diagnosis and throughout ongoing disease monitoring efforts to ensure selection of the best treatment plan for an individual patient. However, current prognostic modalities rely primarily on clinical features.

CGIs MatBA-DLBCL microarray provides clinicians with information on genomic alterations in DLBCL, including regions of gain and loss that are associated with disease outcome.

A research collaboration between the Memorial Sloan-Kettering Cancer Center and CGI using 87 patient samples, as well as the analysis of two open datasets including 171 samples (GSE11318, Lenz et al.) and 51 high risk samples (E-MEXP-3463, Taskinen) and other published datasets showed that:

CGI believes that it is the only laboratory to have a CLIA and New York State approved microarray for the genomic assessment of DLBCL. The MatBA-DLBCL Array CGH assay joins the DLBCL CompleteSM program offered by CGI, which includes a suite of esoteric tests used in the diagnosis, prognosis and clinical management of DLBCL patients. This newly-approved DLBCL test extends CGIs ongoing commitment to developing new diagnostic and disease management tools for some of the most costly and critical unmet needs in oncology today. MatBA-DLBCL joins MatBA-CLL (chronic lymphocytic leukemia) and MatBA-SLL (small lymphocytic leukemia) in CGIs suite of CLIA- and New York State-approved proprietary microarrays for the clinical management of underserved hematological malignancies.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited. In addition, we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. The company has been built on a foundation of world-class scientific knowledge and IP in solid and hematologic cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.

CGIs dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new oncology tests. CGIs full-service cancer genetic practice and path to innovation with research makes for optimal patient care management. For further information, please see http://www.cancergenetics.com.

See more here:
Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL, A Proprietary Microarray Test for the Diagnosis ...

Myriad Genetics Inc. (MYGN)s Australian court victory recognizing its ownership of patents for genes linked to cancer risks will be appealed by a group representing cancer patients, a law firm said.

Cancer Voices Australia and Yvonne DArcy, a Brisbane resident diagnosed with breast cancer, sued in 2010 to stop Myriad and Genetic Technologies Ltd. (GTG) from patenting an isolated DNA associated with an increased risk of breast and ovarian cancers, according to Maurice Blackburn Lawyers. The firm said it has filed the appeal in the Federal Court of Australia today.

We intend to continue the challenge to the monopoly created by the patent held by Myriad, Rebecca Gilsenan, a lawyer at Melbourne-based Maurice Blackburn, said in an e-mailed statement.

The issue has divided the global medical community, with groups including the Association for Molecular Pathology and the American College of Medical Genetics arguing that Myriad is trying to get legal ownership of parts of the human body. The U.S. Court of Appeals for the Federal Circuit, which specializes in patent law, has twice ruled that genes can be patented.

The Myriad case returns to the U.S. Supreme Court this year after the U.S. high court agreed Nov. 30 to hear the Association for Molecular Pathologys appeal.

Australian Federal Court Justice John Nicholas ruled Feb. 15 that the method used by Myriad and Genetic Technologies of purging a gene of biological material is a manufacturing process that can be patented.

Some scientists argue they have been stymied in researching new medicines and treatments because they may come up against demands for royalties or letters demanding they stop using patented inventions. Companies such as Genomic Health Inc. (GHDX) have argued they cant attract investment dollars if they cant protect their research from competitors.

I wont give up the fight, DArcy said in todays statement. We need to continue for future generations of people who at some point in their life, may need treatment for cancer and other diseases.

The case is: Cancer Voices Australia v. Myriad Genetics. NSD643/2010. Federal Court of Australia (Sydney).

To contact the reporter on this story: Joe Schneider in Sydney at jschneider5@bloomberg.net

See the article here:
Myriad Genetics Win on Gene Patent Ownership Is Appealed

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU), which is pioneering the use of genetic information for the prevention and improved management of certain chronic conditions of aging, today announced that it has entered into a three year Preferred Participation Agreement with Renaissance Health Service Corporation, and certain of its affiliates and subsidiaries, (collectively RHSC). Pursuant to the Agreement, RHSC has agreed to reimburse Interleukin a fixed price for each PST genetic test that it processes for a customer of RHSC.

Interleukins proprietary PST genetic risk panel for periodontal disease severity and tooth loss susceptibility addresses the need to identify individuals who are at greater risk of severe periodontitis, a primary cause of tooth loss.

We are encouraged by RHSCs efforts to advance personalized health in dentistry through the use of our unique periodontal susceptibility risk test, PST, said Kenneth S. Kornman, CEO, Interleukin Genetics.

About Renaissance Health Service Corporation

Renaissance Health Service Corporation (RHSC) is the parent organization for a family of companies that are leaders in the dental insurance industry. RHSC companies are among the largest and oldest group of dental benefit providers in the United States, covering 11 million people and paying out nearly $3 billion in dental benefits in 2012. Currently, the companies employ approximately 1,200 people, who are located in Indianapolis, Indiana; Sherwood and Little Rock, Arkansas; Louisville, Kentucky; Okemos and Farmington Hills, Michigan; Albuquerque, New Mexico; Raleigh and Charlotte, North Carolina; Columbus and Cleveland, Ohio; and Nashville, Knoxville, and Memphis, Tennessee.

About Interleukin Genetics

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Certain statements contained herein are forward-looking statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, risks related to the adequacy of the Companys capital resources and the need for additional funding, that the offering of dental plans by RHSC affiliates that include the PSTtest will be delayed significantly, that RHSC affiliates may not be successful in developing or marketing such dental plans, and that such dental plans may not be accepted by dental customers, as well as the risks and uncertainties described in the Companys annual report on Form 10-K for the year ended December 31, 2011 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

Original post:
Interleukin Genetics and Renaissance Health Service Corporation Enter into a Preferred Participation Agreement for ...

Laura King Edwards was a high school junior when her sister Taylor was born in 1998.

Despite the age difference, they became very close.

When Taylor was 1, Lauras summer job was babysitting, five days a week, 10 hours a day. They spent afternoons curled up on the couch, watching TV or taking naps.

She called me Rar Rar before she could say my name, Laura recalls. I called her T.

Taylor taught herself to read at 3 and excelled in kindergarten. But in first grade, she began having trouble with homework and with her vision. She was diagnosed with retinitis pigmentosa, an inherited disorder that causes a gradual vision loss.

But that turned out to be wrong. In 2006, just three weeks before her eighth birthday, Taylor got an even more devastating diagnosis neuronal ceroid lipofuscinosis, also called Batten disease.

When Laura Googled the words, she read only a few sentences before she started to cry.

Batten disease is a rare, inherited neurodegenerative disease that results in the death of neurons in the brain, retina and central nervous system.

Early symptoms are vision loss, seizures, clumsiness and personality changes. Eventually, it leaves children blind, bedridden and unable to communicate. There is no known cure or effective treatment.

To get the disease, Taylor had to inherit a defective copy of a particular gene from each of her parents. Her sister Laura got one good copy and one bad copy, so shes a carrier, which means shes healthy but could pass the gene on to her children.

Read the original here:
Charlotte family funds research into gene therapy for rare Batten disease

The first adult animal to be cloned was Dolly the sheep.   At the time (1997) the event was seen as a remarkable technological feat, of importance primarily to research biologists.   In the decade that followed other animals were cloned in research laboratories around the world.   Initial success rates were low, but in recent years the techniques have improved to the point that the cloning of adult animals is becoming economically feasible.

For example, a Texas company called Crestview Genetics is now in the business of cloning polo ponies.   Polo is a big sport in many countries, and good polo ponies are in great demand.  According to an article a polo trade journal, a three-month-old clone of a polo pony called Cuartetera sold for $800,000 in Argentina in 2010.  Crestview expects to be able to create up to 30 clones of valuable polo ponies and horses a year. You do the math.

Cloning animals for a profit is likely to become even more commonplace within the next decade.   The most likely candidates, obviously, are animals that are worth a lot to somebody, like prizewinning bulls for breeding cattle; championship dogs; rare or endangered animals; even beloved pets. How much would you be willing to pay to have your pet cloned?Source:
http://humanbiologyblog.blogspot.com/2013/02/cloning-goes-commercial.html

Persons with potentially life-threatening allergic reactions to specific allergens (such as bee stings or certain foods) are told to carry an epinephrine auto-injector with them at all times.  A typical epinephrine auto-injector (such as an EpiPen) is a device about 5 ½ inches in length by one inch in diameter containing a single dose of injectable epinephrine.  When an allergic reaction occurs, the user is supposed to inject the epinephrine into his/her thigh as soon as possible.  I carried an EpiPen myself for a time, after I suffered a severe allergic reaction to multiple stings by ground-dwelling yellow jacket wasps.  But as time went by I stopped carrying it because it just didn’t seem necessary, and because carrying it every day was inconvenient.  Fortunately, I’ve never had another severe allergic reaction like that first one.  But what if I did?

Now there’s an alternative, called Auvi-Q.  Auvi-Q is still just a single dose of injectable epinephrine.  But Auvi-Q is shaped entirely differently; it’s about the length and width of a credit card and the width of a smart-phone.  The manufacturer hopes that it will appeal to the younger generation used to carrying credit/debit cards and phones.  More importantly, once the cover is removed Auvi-Q talks the user through the entire process of injection with a soothing human voice. (To hear the instructions, view the video on the Auvi-Q website.)  The verbal instructions may be helpful to some users and caregivers, since it may be years before the device is needed and one could forget how to use the device in that time.

The maker of Auvi-Q hopes that younger persons will find the device “cool”, and so perhaps they’ll be more willing to carry it than the EpiPen.  (The manufacturer of the EpiPen takes issue with an Auvi-Q marketing claim that 2/3 of EpiPen users don’t actually carry their EpiPen with them.)  Time will tell whether Auvi-Q is different enough to find a place in the competitive epinephrine auto-injector market.

Source:
http://humanbiologyblog.blogspot.com/2013/03/auvi-q-alternative-to-epipen.html

The Farrier #39;s Role with Stem Cell Therapy
At the 2013 International Hoof-Care Summit in Cincinnati, Ohio, Frank Reilly, DVM, talks about the farrier #39;s role in the use of stem cells.

By: AFJTV

Read more here:
The Farrier's Role with Stem Cell Therapy - Video

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

Go here to see the original:
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy - Video

Cerebral Palsy Before and After Stem Cell Therapy Comparison
Cerebral Palsy Before and After Stem Cell Therapy Comparison video Stem Cell Therapy done at Dr Alok Sharma NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Continue reading here:
Cerebral Palsy Before and After Stem Cell Therapy Comparison - Video

Stem Cell Therapy for Autism Part 2
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy Psychology assessment: 1) Now his duration of expressing his anger has reduced (ie) previously he would get angry and it would continue for half an hour to 20 minutes. Now it has reduced to 10 minutes. 2) Now his level of understanding and tolerance level has increased (ie) before he would get upset even before his parents spoke whereas now he listens to them and follows commands. 3) Now he has started writing (ie) now he can copy from the book and he can do so for a duration of ½ hour to 1 hour which wasn #39;t possible at all before. 4) Previously he had obsessive features like washing his hands repetitively but now it has reduced. 5) Previously he would disturb others in the classroom by shouting or sitting next to them but now he doesn #39;t disturb others ...

By: neurogenbsi

Go here to read the rest:
Stem Cell Therapy for Autism Part 2 - Video

SALT LAKE CITY, Feb. 28, 2013 /PRNewswire/ --Discgenics announces the successful completion of an animal study demonstrating safety and efficacy of its novel therapy for reducing back pain caused by degenerative disc disease. This product, known as Injectable Discosphere Cell Therapy (IDCT), features Discgenics' patented, allogeneic, human disc-derived stem cell technology. The study showed that after one injection of IDCT in degenerated discs there was a restoration of disc height and tissue architecture, while noting no inflammatory response.

Discgenics CEO Flagg Flanagan said, " We are very encouraged by the results of the small animal pilot study as it shows the initial safety and efficacy of IDCT, which is produced from adult human disc-derived stem cells.We are optimistic that these early results will be indicative of our therapy's performance in further animal studies and will accelerate us toward human clinical studies and, ultimately, to an FDA cleared product.We believe this technology will revolutionize the way back pain is treated." Discgenics is currently conducting further studies of safety and efficacy in multiple animal species to support future scientific publications and for use in gaining regulatory clearance.

About Discgenics, Inc.

Discgenics is a privately funded spinal therapeutics company that is utilizing adult human disc stem cells within a tissue engineering approach to treat patients debilitated by degenerative disc disease. News and other information on the company are available at: http://www.discgenics.com.

Read more:
Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphereâ„¢ Cell Therapy

Prof. Jean-Marie Lehn at MU part 2
Nobel Laureate for Chemistry Prof. Jean-Marie Lehn #39;s lecture and dialogue "Supramolecular chemistry: Contributions to biotechnology and nanotechnology" on Friday, January 7, 2005 at the National Genetic Engineering and Biotechnology Center (BIOTEC) of the Ministry of Science and Technology at the Thailand Science Park, Rangsit

By: PeaceFoundationNET

See original here:
Prof. Jean-Marie Lehn at MU part 2 - Video

Prof. Jean-Marie Lehn at MU part 1
Nobel Laureate for Chemistry Prof. Jean-Marie Lehn #39;s lecture and dialogue "Supramolecular chemistry: Contributions to biotechnology and nanotechnology" on Friday, January 7, 2005 at the National Genetic Engineering and Biotechnology Center (BIOTEC) of the Ministry of Science and Technology at the Thailand Science Park, Rangsit

By: PeaceFoundationNET

Read the original:
Prof. Jean-Marie Lehn at MU part 1 - Video

Champion Drive Genetics - 2013 Sire Line-Up
Champion Drive Genetics - 2013 Sire Line-Up - created at animoto.com

By: diamondgcattleco

Read the rest here:
Champion Drive Genetics - 2013 Sire Line-Up - Video

DoNUT Genetics
THIS VIDEO IS DETICATED TO THE FOLLOWING (in alphabetical order)~ Chestersee D-trix of theDOMINICshow Grace Helbig of My Damn Channel Hannah Hart of My Drunk Kitchen Jenna Marbles Mamrie Hart of You Deserve a Drink MaxNoSleeves Ryan Higa of HigaTV, and nigahiga + many more Swoozie06 SO PLEASE!!! Watch it!! First video! Please bear with us Please please please watch it all the way through!!! Comments and subscriptions and kind criticism would be deeply appreciated. this was a video Conceived of and made within 2 hours. I #39;m sure you understand. PLEASE NOTE - We did not tag these youtube celebs for views/subscribers. We just love them very much and wanted them to see (and hopefully love) this video. THANK YOU SOOOO MUCH FOR WATCHING OUR AMATEURISHNESS!

By: AprilRosyChampagne59

Follow this link:
DoNUT Genetics - Video

Diabetes: What is it and how did I get it?
Dr. Kotansis understands that every patient has a unique set of symptoms, conditions, circumstances and needs. He will listen, investigate your history and research the interactions in your genetics, environment, lifestyle, and diet.

By: TheKotsanisInstitute

See original here:
Diabetes: What is it and how did I get it? - Video

10 Amazing Facts About Fungi
A fungus (pron.: / #712;f #652; #331; #609; #601;s/; plural: fungi[3] or funguses[4]) is a member of a large group of eukaryotic organisms that includes microorganisms such as yeasts and molds (British English: moulds), as well as the more familiar mushrooms. These organisms are classified as a kingdom, Fungi, which is separate from plants, animals, and bacteria. One major difference is that fungal cells have cell walls that contain chitin, unlike the cell walls of plants, which contain cellulose. These and other differences show that the fungi form a single group of related organisms, named the Eumycota (true fungi or Eumycetes), that share a common ancestor (a monophyletic group). This fungal group is distinct from the structurally similar myxomycetes (slime molds) and oomycetes (water molds). The discipline of biology devoted to the study of fungi is known as mycology (from the Greek mu; #973; kappa; eta; sigmaf;, muk #275;s, meaning "fungus"). Mycology has often been regarded as a branch of botany, even though it is a separate kingdom in biological taxonomy. Genetic studies have shown that fungi are more closely related to animals than to plants. Abundant worldwide, most fungi are inconspicuous because of the small size of their structures, and their cryptic lifestyles in soil, on dead matter, and as symbionts of plants, animals, or other fungi. They may become noticeable when fruiting, either as mushrooms or molds. Fungi perform an essential role in the decomposition of organic matter and have fundamental roles in ...

By: MovieMania1506

Excerpt from:
10 Amazing Facts About Fungi - Video

Why was Gregor Mendel Ignored? Genetics in the 1800s - DP 2.7 Blueprint of Life HSC Biology
The reasons of why Robert Mendel was ignored and not taken seriously in the 1800s for his experiments on heredity. This is a quick overview for HSC students studying dot point 2.7 of the blueprint of life syllabus

By: hscbiologyexposed

Continue reading here:
Why was Gregor Mendel Ignored? Genetics in the 1800s - DP 2.7 Blueprint of Life HSC Biology - Video

BJORN HEYHEIM
Innovative solutions in genomics applications for sea bass and sea bream Athens, Greece, 11th October 2012 INTRANEMMA - MARINE GENOMICS for USERS Salmon aquaculture in Norway, breeding and genomics Bjørn Høyheim Norwegian School of Veterinary Science Department for Basic Sciences and Aquatic Medicine, Section for Genetics http://www.intranemma.eu

By: intranemma

Go here to see the original:
BJORN HEYHEIM - Video

Pedigree Charts
A simple description of how to create a pedigree chart in genetics.

By: Jennifer DesRochers

More:
Pedigree Charts - Video

LASER GENETICS DESIGNATOR ND3x50
I created this video with the YouTube Video Editor (www.youtube.com

By: erison bmx

View original post here:
LASER GENETICS DESIGNATOR ND3x50 - Video

Mandala Seeds : "Point Of No Return" *Cannabis Grow* Day 60 of Flower
Just flushed with distilled water. Will harvest in 7-10 days. This was the mother plant I started from seed anddecided to flower because the genetics of clones were superior in quality and growth characteristics. I Highly Recommend Mandala Seeds! Point of No Return Type: indica/sativa Genetics: Afghanistan; Mexico Cultivation: indoor/outdoor/greenhouse THC: 15,5%, CBD: 0,5% High: Predominantly knockout medical-grade indica stone; couch lock; body relaxation. Aroma: Peppermint; sweet; fruity-berry; maracuja. Medical use: Deep and long lasting medical effects; suitable for pain relief, reducing MS related spasms, hyperactivity nervousness, anxiety, stress related symptoms, sleep disorders, menstrual cramps, muscle relaxant. Flowering time outdoor: mid-October (south), late October (north) Flowering time indoor: 65-72 days Recommended light intensity: 400-600W HPS/m2 Yield (dry weight): 350-400 gr/m2; 100+ gr. per plant in greenhouse; 700-1000 gr. per plant outdoor in the ground. Plant Height: medium Detailed Description: This exceptional medical strain should not be missing in any garden if you are looking for a one-hit wonder with a good yield and delicious aroma. Point of No Return (PNR) delivers a beautiful crop of thick cone-shaped buds crowned by towers of resiny calyxes. The long head bud tapers at the end like a peak and has a sufficiently airy structure that contributes to the high mold resistance. Although this is not a large plant it focuses a tremendous amount ...

By: rockyta21

Read more:
Mandala Seeds : "Point Of No Return" *Cannabis Grow* Day 60 of Flower - Video

Lot 12 1215 full brother
Homestead Genetics Bull Sale March 30 2013, full brother to Lot 12

By: Summerrain411

More here:
Lot 12 1215 full brother - Video

Lot 12 20120209044053
Homestead Genetics Bull Sale March 30 2013, yearling heifer

By: Summerrain411

Read the original:
Lot 12 20120209044053 - Video